A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Siremadlin (Primary) ; Cytarabine; Cytarabine/daunorubicin; Daunorubicin; Idarubicin; Midazolam; Midostaurin; Posaconazole
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 03 Oct 2019 Planned End Date changed from 18 Apr 2023 to 13 Jun 2023.
- 08 Aug 2019 Planned End Date changed from 13 Jan 2023 to 18 Apr 2023.
- 11 Jul 2019 Planned initiation date changed from 28 Feb 2019 to 31 Jul 2019.